J.P. Morgan Publishes 3Q/11 Preview on Specialty Pharmaceuticals
JP Morgan has published a research report on commenting on the important updates coming out of 3Q results for the Specialty Pharmaceuticals group.
In the report, JP Morgan writes, “While our overall 3Q estimates are roughly in line with consensus, we see a number of important updates coming out of 3Q results for the specialty Pharma group. In particular, we focus on WCRX (latest capital deployment comments following a 3Q sell-off), VRX (following last quarter's controversial results) as well as ENDP (first full post-AMS quarter)… Overall, following a sharp pullback in the group during the quarter, we see a number of attractive opportunities in the specialty pharma group with WCRX, MRX and ENDP (all OW rated) representing our favorites in the space”.
Companies included in the J.P. Morgan report are: Allergan (NYSE: AGN), Endo Pharmaceuticals (NASDAQ: ENDP), Forest Laboratories (NYSE: FRX), Medicis Pharmeceutical (NYSE: MRX), Valeant Pharmaceuticals (NYSE: VRX), and Warner Chilcott (NASDAQ: WCRX)
